Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968488 | 0.88 | HTT (1.00) | HTTKMT2ATSHRSMN1; SMN2PKM | |
| SCHEMBL15443199 | 0.78 | — | — | |
| SCHEMBL23125676 | 0.74 | — | — | |
| SCHEMBL962662 | 0.74 | KMT2A (0.75) | HTTKMT2APOLB | |
| SCHEMBL2760109 | 0.73 | HTT (0.77) | HTTKMT2ATSHRSMN1; SMN2PKM | |
| SCHEMBL15429708 | 0.73 | SMN1; SMN2 (0.76) | HTTKMT2ASMN1; SMN2PKMMEN1 | |
| SCHEMBL965286 | 0.73 | KMT2A (0.82) | HTTKMT2APOLBCHRM1 | |
| SCHEMBL19741751 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL3852849 | 0.72 | KMT2A (0.72) | HTTKMT2ASMN1; SMN2MEN1POLB | |
| SCHEMBL17273858 | 0.71 | KMT2A (0.78) | HTTKMT2ASMN1; SMN2MEN1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HTT 1294/4885KMT2A 3803/4885TSHR 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.